New registry aims to boost lung transplants by reconditioning donor lungs

NCT ID NCT05101460

Ongoing Disease control Sponsor: XVIVO Perfusion Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This registry follows 315 people who received a lung transplant after the donor lung was treated with the XVIVO Perfusion System, a device that keeps lungs warm and oxygenated outside the body. Researchers are tracking survival and lung function for up to 5 years to see how well these lungs perform long-term. The goal is to gather real-world data on safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XVIVO Perfusion System with STEEN Solution
What this could lead to: If successful, this could confirm that EVLP helps more donor lungs become usable for transplant, potentially increasing the number of lung transplants available.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove EVLP is better than standard care. Results may not apply to all transplant centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG TRANSPLANT

Contacts and locations

Locations

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.